PhoreMost Limited, a UK-based biopharmaceutical company dedicated to developing drugs against intractable disease targets, and Oxford Biomedica plc, a gene and cell therapy group, have entered into a discovery collaboration to develop next-generation CAR-T cell therapies. Financial details of the agreement were not disclosed.   As a part of the agreement, PhoreMost will deploy its in-house expertise and next-generation phenotypic screening platform, SITESEEKER, to identify therapeutic candidat...